Format

Send to

Choose Destination
J Clin Neuromuscul Dis. 2015 Sep;17(1):1-5. doi: 10.1097/CND.0000000000000083.

Fludarabine in the Treatment of Refractory Chronic Inflammatory Demyelinating Neuropathies.

Author information

1
*Department of Neurology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ; †Department of Medicine, Columbia University, New York, NY; and ‡Department of Neurology, Neurological Institute, Columbia University, New York, NY.

Abstract

Inflammatory demyelinating neuropathies have variable responses to immunomodulating therapy. Eight patients with chronic inflammatory neuropathies who were refractory to standard therapy were treated with fludarabine, a combination of fludarabine and cyclophosphamide, and in 1 case with fludarabine and rituximab. Five patients with immunoglobulin M anti-myelin-associated glycoprotein neuropathies received fludarabine. Three patients with chronic inflammatory demyelinating polyneuropathy received a combination of fludarabine and cyclophosphamide. All 8 patients improved in either functional status or strength with minimal toxicities. Most patients experienced sustained remission after the use of fludarabine or fludarabine and cyclophosphamide. Fludarabine alone or in combination with cyclophosphamide should be considered for patients with inflammatory demyelinating neuropathies, refractory to other treatments.

PMID:
26301372
DOI:
10.1097/CND.0000000000000083
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center